• Forum
  • Aktiemarknader
    • BörsRealtidskurser, index och marknadsutveckling
    • MorgonrapportDaglig marknadssammanfattning och nattens viktigaste händelser
    • BörskalenderKommande resultat, noteringar och företagshändelser
    • UtdelningskalenderKommande och tidigare utdelningar
  • Bolag
    • BolagBläddra och filtrera hela listan över noterade bolag
    • UpptäckInspiration till din nästa investering
    • BörsnoteringarNya noteringar och kommande börsintroduktioner
    • ÅrsstämmorDatum för årsstämmor och aktieägarinformation
  • Aktieforskning
    • AktieanalysExpertaktieanalys och rekommendationer
    • ArtiklarNyheter, insikter och marknadskommentarer
    • PortföljInderes modellportfölj
    • inderesTVVideohub för aktieanalys, forskning och expertkommentarer
    • TranskriptionerFullständiga utskrifter av resultatsamtal och investerarmöten
    • AktiejämförelseJämför nyckeltal och utveckling för flera aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Q&A
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer

Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.

Photocure ASA - Share option grant

PHORegulatoriskt pressmeddelande2026-07-29 21:48
Oslo, Norway, 29 July 2026 - Photocure ASA (the "Company") (OSE: PHO) has
granted share options to employees.

A total of 265,000 share options, equal to 0.98% of total shares issued in the
Company, were granted to the executive leadership team at an exercise price at
NOK 63,93 per share (the "ELT Options"). The exercise price is equal to the
weighted average share price 30 trading days before day of grant with an
additional premium of 10% on top of the calculated average price.

The ELT Options are granted in accordance with Photocure's long term incentive
program and the Company's guidelines for remuneration of senior executives (the
"Guidelines"), as approved by Photocure's annual general meeting held 26 June
2026. The share option program and properties of the options are further
described in the Guidelines.

The following ELT Options were granted to primary insiders:

·           Daniel Schneider, President and Chief Executive Officer, 100,000
options

·           Geoffrey Coy, Vice President and General Manager North America,
40,000 options

·           Jane Healy, Vice President and General Manager Europe, 50,000
options

·           Anders Neijber, Chief Medical Officer, Global Medical Affairs and
Clinical Development and R&D, 40,000 options

·           Anja Gossens-Von Der Heidt, Head of Global Human Resources, 35,000
options

Primary insider notifications pursuant to the market abuse regulation article 19
are attached.

For further information, please contact:

Priyam Shah

Vice President Investor Relations

Tel : +17176815072

Email: priyam.shah@photocure.com

About Photocure ASA

Photocure is a commercial diagnostic company with global reach, committed to
driving progress in uro-oncology precision diagnostics, delivering meaningful
advances for patients with urological cancers. Our unique core technology has
led to better health outcomes for patients worldwide. The company aims to
provide an array of transformative solutions that help physicians with timely
diagnostic information, to inform more personalized decisions on how best to
manage each individual patient. Photocure is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit
www.photocure.com/news

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.
he\
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading\
Act.\